Search

Imdevimab

[L23524] In November 2021, the same indication was approved by the EMA.

Ceftriaxone

[A215582] It has a very long half-life compared to other cephalosporins and is high penetrable into the meninges[A215582], eyes[A215647], and inner ear[A215627].

Iroxanadine

It induces phosphorylation of p38 SAPK, which plays an important role in EC homeostasis. endothelial cell (EC). … EC function plays a central role in vascular diseases (e.g. atherosclerosis, restenosis, diabetic angiopathies, microvascular angina, peripheral arterial disease).

Ganaxolone

[L41135] In July 2023, ganaxolone was also approved under the same brand name and for the same indication by the EMA.[L47636] … [A3197] Endogenous neurosteroids, which comprise certain metabolites of progesterone and deoxycorticosterone, bind potently and specifically to GABA_A receptors to enhance their inhibitory effects

Recombinant Cholera Toxin B Subunit

Recombinant Cholera Toxin B Subunit is an ingredient in the EMA-authorised product Dukoral.

Chondroitin sulfate

[A32063] Chondroitin sulfate is sold as an OTC dietary supplement in North America and it is a prescription drug under the EMA in Europe.[A32066]

Tetrabenazine

A drug formerly used as an antipsychotic but now used primarily in the symptomatic treatment of various hyperkinetic disorders. It is a monoamine depletor and used as symptomatic treatment of chorea associated with Huntington's disease. ...

Ranibizumab

[L41399] In August 2022, other biosimilars CIMERLI, RAIVISIO, and RANOPTO were approved by the FDA, EC, and Health Canada respectively.[L42625,L43513,L49141] … [A246399] Ranibizumab was initially approved by the FDA in 2006 [A2301] and by the European Commission (EC) in 2007.[L41429] It is marketed under the brand names LUCENTIS and SUSVIMO.

Sodium borate

rdESAT-6

rdESAT-6 is a recombinant dimer of Mycobacterium tuberculosis early secretory antigenic target used as an ingredient in the diagnostic agent SIILTIBCY along with rCFP-10.